CN104136023A - 降低心血管疾病风险的方法 - Google Patents
降低心血管疾病风险的方法 Download PDFInfo
- Publication number
- CN104136023A CN104136023A CN201380004642.2A CN201380004642A CN104136023A CN 104136023 A CN104136023 A CN 104136023A CN 201380004642 A CN201380004642 A CN 201380004642A CN 104136023 A CN104136023 A CN 104136023A
- Authority
- CN
- China
- Prior art keywords
- patient
- compound
- ldl
- formula
- statins
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
Description
Claims (23)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910123564.7A CN110025608A (zh) | 2012-01-06 | 2013-01-04 | 降低心血管疾病风险的方法 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261584002P | 2012-01-06 | 2012-01-06 | |
US61/584,002 | 2012-01-06 | ||
PCT/US2013/020317 WO2013103842A1 (en) | 2012-01-06 | 2013-01-04 | Methods of reducing risk of cardiovascular disease |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910123564.7A Division CN110025608A (zh) | 2012-01-06 | 2013-01-04 | 降低心血管疾病风险的方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN104136023A true CN104136023A (zh) | 2014-11-05 |
Family
ID=48745439
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201380004642.2A Pending CN104136023A (zh) | 2012-01-06 | 2013-01-04 | 降低心血管疾病风险的方法 |
CN201910123564.7A Pending CN110025608A (zh) | 2012-01-06 | 2013-01-04 | 降低心血管疾病风险的方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910123564.7A Pending CN110025608A (zh) | 2012-01-06 | 2013-01-04 | 降低心血管疾病风险的方法 |
Country Status (9)
Country | Link |
---|---|
US (2) | US10028926B2 (zh) |
EP (2) | EP3735967A1 (zh) |
JP (2) | JP6295205B2 (zh) |
CN (2) | CN104136023A (zh) |
AU (1) | AU2013207423B2 (zh) |
CA (1) | CA2861643C (zh) |
HK (1) | HK1201452A1 (zh) |
MX (1) | MX367352B (zh) |
WO (1) | WO2013103842A1 (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108348491A (zh) * | 2015-11-06 | 2018-07-31 | 燿石治疗公司 | 治疗混合性血脂异常 |
CN108697677A (zh) * | 2016-02-26 | 2018-10-23 | 燿石治疗公司 | 对正接受降脂疗法的纯合型家族性高胆固醇血症患者的治疗 |
CN109666727B (zh) * | 2018-12-29 | 2020-11-06 | 中国药科大学 | 一种高活性抑制pcsk9表达的微小rna的用途 |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2600901B1 (en) | 2010-08-06 | 2019-03-27 | ModernaTX, Inc. | A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof |
ES2737960T3 (es) | 2010-10-01 | 2020-01-17 | Modernatx Inc | Nucleósidos, nucleótidos y ácidos nucleicos modificados y sus usos |
AU2012236099A1 (en) | 2011-03-31 | 2013-10-03 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
EP3682905B1 (en) | 2011-10-03 | 2021-12-01 | ModernaTX, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
EP2791160B1 (en) | 2011-12-16 | 2022-03-02 | ModernaTX, Inc. | Modified mrna compositions |
US9440754B2 (en) | 2012-03-29 | 2016-09-13 | R.P. Scherer Technologies, Llc | Three circuit fill system for blow fill seal containers |
AU2013243948A1 (en) | 2012-04-02 | 2014-10-30 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins associated with human disease |
US9303079B2 (en) | 2012-04-02 | 2016-04-05 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9255154B2 (en) | 2012-05-08 | 2016-02-09 | Alderbio Holdings, Llc | Anti-PCSK9 antibodies and use thereof |
EP4074834A1 (en) | 2012-11-26 | 2022-10-19 | ModernaTX, Inc. | Terminally modified rna |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
BR112015026513A2 (pt) | 2013-04-17 | 2017-07-25 | Pfizer | derivados de n-piperidin-3-ilbenzamida para tratar as doenças cardiovasculares |
CA2926218A1 (en) | 2013-10-03 | 2015-04-09 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
CA2966631A1 (en) | 2014-11-14 | 2016-05-19 | Gemphire Therapeutics Inc. | Processes and intermediates for preparing alpha, omega-dicarboxylic acid-terminated dialkane ethers |
CN107530307A (zh) | 2015-03-13 | 2018-01-02 | 艾斯柏伦治疗公司 | 包含etc1002和依泽替米贝的固定剂量组合和制剂以及治疗心血管疾病或降低心血管疾病风险的方法 |
MA41793A (fr) * | 2015-03-16 | 2018-01-23 | Esperion Therapeutics Inc | Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire |
US20210361618A1 (en) * | 2017-02-08 | 2021-11-25 | Esperion Therapeutics, Inc. | Triplet combination formulations and methods for treating or reducing the risk of cardiovascular disease |
KR20200054910A (ko) * | 2017-04-18 | 2020-05-20 | 젬파이어 세러퓨틱스 인코포레이티드 | 젬카빈, 이의 약학적으로 허용 가능한 염, 조성물 및 이의 사용 방법 |
US20190008779A1 (en) * | 2017-05-11 | 2019-01-10 | Gemphire Therapeutics Inc. | Gemcabene compositions and methods of use thereof |
CA3144371A1 (en) | 2019-06-21 | 2020-12-24 | Esperion Therapeutics, Inc. | Methods of making bempedoic acid and compositions of the same |
CN113134086A (zh) * | 2020-01-20 | 2021-07-20 | 深圳市长卿医学研究院 | 一种降血脂的药物组合物 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5648387A (en) * | 1995-03-24 | 1997-07-15 | Warner-Lambert Company | Carboxyalkylethers, formulations, and treatment of vascular diseases |
WO1999030704A1 (en) * | 1997-12-12 | 1999-06-24 | Warner-Lambert Company | Statin-carboxyalkylether combinations |
US20090312355A1 (en) * | 2006-08-03 | 2009-12-17 | Trustees Of Tufts College | Non-Flushing Niacin Analogues, and Methods of Use Thereof |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6861555B2 (en) | 2000-01-25 | 2005-03-01 | Warner-Lambert Company | Calcium dicarboxylate ethers, methods of making same, and treatment of vascular disease and diabetes therewith |
US20020103252A1 (en) | 1997-12-12 | 2002-08-01 | Bisgaier Charles Larry | Statin-carboxyalkylether combinations |
BR0009520A (pt) | 1999-04-01 | 2002-06-11 | Esperion Therapeutics Inc | Composto, método para sintetizar o mesmo, composição, metódos para o tratramento ou prevenção, em um paciente, de doença cardiovascular, dislipidemia, dislipoproteinemia, distúrbio de metabolismo de glucose, doença de alzheimer, sìndrome x ou sìndrome metabólica, septicemia, distúrbio trombótico, distúrbio associado com receptor ativado por proliferador de peroxissoma, obesidade, pancreatite, hipertensão, doença renal, câncer, inflamação, impotência, para reduzir o teor de gordura de carne de gado bovino, e, para reduzir o teor de colesterol de ovos de aves |
BR0114617A (pt) | 2000-10-11 | 2005-12-13 | Esperion Therapeutics Inc | Composto, composição farmacêutica, métodos para tratar ou previnir uma doença cardiovascular, uma dislipidemia, uma dislipoproteinemia, um distúrbio do metabolismo da glicose, trombótico e associado com o receptor ativado do proliferador de peroxissoma, a doença de alzheimer, a sìndrome x ou sìndrome metabólica, a septicemia, a obesidade, pancreatite, a hipertensão, doença renal, câncer, a inflamação e a impotência, em um paciente e para reduzir o teor de gordura da carne em animal de criação e de colesterol de ovos de aves domésticas |
US6645170B2 (en) | 2001-03-05 | 2003-11-11 | Bioject Medical Technologies, Inc. | Simplified disposable needle-free injection apparatus and method |
US20040229954A1 (en) * | 2003-05-16 | 2004-11-18 | Macdougall Diane Elaine | Selective manipulation of triglyceride, HDL and LDL parameters with 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt |
US7345190B2 (en) | 2003-11-12 | 2008-03-18 | Ssv Therapeutics, Inc. | Carnitine conjugates as dual prodrugs and uses thereof |
US7579504B2 (en) | 2005-12-07 | 2009-08-25 | Gilead Sciences, Inc. | ABCA1 elevating compounds |
-
2013
- 2013-01-04 EP EP20166700.3A patent/EP3735967A1/en not_active Withdrawn
- 2013-01-04 CA CA2861643A patent/CA2861643C/en active Active
- 2013-01-04 MX MX2014008180A patent/MX367352B/es active IP Right Grant
- 2013-01-04 CN CN201380004642.2A patent/CN104136023A/zh active Pending
- 2013-01-04 US US14/370,722 patent/US10028926B2/en not_active Expired - Fee Related
- 2013-01-04 JP JP2014551345A patent/JP6295205B2/ja active Active
- 2013-01-04 WO PCT/US2013/020317 patent/WO2013103842A1/en active Application Filing
- 2013-01-04 CN CN201910123564.7A patent/CN110025608A/zh active Pending
- 2013-01-04 AU AU2013207423A patent/AU2013207423B2/en active Active
- 2013-01-04 EP EP13733913.1A patent/EP2800564B1/en active Active
-
2015
- 2015-02-27 HK HK15101958.1A patent/HK1201452A1/zh unknown
-
2018
- 2018-02-19 JP JP2018026939A patent/JP2018104452A/ja active Pending
- 2018-06-29 US US16/024,288 patent/US10709678B2/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5648387A (en) * | 1995-03-24 | 1997-07-15 | Warner-Lambert Company | Carboxyalkylethers, formulations, and treatment of vascular diseases |
WO1999030704A1 (en) * | 1997-12-12 | 1999-06-24 | Warner-Lambert Company | Statin-carboxyalkylether combinations |
US20090312355A1 (en) * | 2006-08-03 | 2009-12-17 | Trustees Of Tufts College | Non-Flushing Niacin Analogues, and Methods of Use Thereof |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108348491A (zh) * | 2015-11-06 | 2018-07-31 | 燿石治疗公司 | 治疗混合性血脂异常 |
CN108366957A (zh) * | 2015-11-06 | 2018-08-03 | 燿石治疗公司 | 用于治疗心血管疾病的吉卡宾组合 |
CN108697677A (zh) * | 2016-02-26 | 2018-10-23 | 燿石治疗公司 | 对正接受降脂疗法的纯合型家族性高胆固醇血症患者的治疗 |
CN109666727B (zh) * | 2018-12-29 | 2020-11-06 | 中国药科大学 | 一种高活性抑制pcsk9表达的微小rna的用途 |
Also Published As
Publication number | Publication date |
---|---|
CN110025608A (zh) | 2019-07-19 |
EP2800564A1 (en) | 2014-11-12 |
US10709678B2 (en) | 2020-07-14 |
EP2800564B1 (en) | 2020-05-06 |
CA2861643A1 (en) | 2013-07-11 |
US20180303779A1 (en) | 2018-10-25 |
JP6295205B2 (ja) | 2018-03-14 |
AU2013207423A1 (en) | 2014-07-24 |
HK1201452A1 (zh) | 2015-09-04 |
AU2013207423B2 (en) | 2017-10-12 |
EP2800564A4 (en) | 2015-07-22 |
JP2018104452A (ja) | 2018-07-05 |
US20150005386A1 (en) | 2015-01-01 |
WO2013103842A1 (en) | 2013-07-11 |
MX367352B (es) | 2019-08-16 |
US10028926B2 (en) | 2018-07-24 |
JP2015503588A (ja) | 2015-02-02 |
EP3735967A1 (en) | 2020-11-11 |
MX2014008180A (es) | 2014-10-14 |
CA2861643C (en) | 2020-10-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104136023A (zh) | 降低心血管疾病风险的方法 | |
US20220110904A1 (en) | Fixed dose combinations and formulations comprising etc1002 and one or more statins and methods of treating or reducing the risk of cardiovascular disease | |
US10912751B2 (en) | Fixed dose combinations and formulations comprising ETC1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease | |
WO2013136277A1 (en) | Pharmaceutical compositions for treatment of cardiovascular diseases | |
JP2009540003A (ja) | Aa1raの低頻度投与を含む腎機能の長期間にわたる改善 | |
WO2020041799A1 (en) | Methods for reducing the risk of diabetes in patients being treated for high cholesterol-related illnesses | |
JP2018027953A (ja) | 膵炎を治療するためのゲムカベンおよび誘導体 | |
AU2019315823A1 (en) | New use of carbamate beta phenylethanolamine analogues for enhancing intracellular clearance of ldl cholesterol and for combining therapy with statins to enhance the efficacy and reduce adverse effects | |
JP2014509305A5 (zh) | ||
KR102662102B1 (ko) | 심혈관 위험의 치료 또는 감소를 위한 etc1002 및 하나 이상의 스타틴을 포함하는 고정 용량 조합 | |
CN102416015A (zh) | 一种含他汀类药物的组合物及其用途 | |
AU2015202580B2 (en) | Gemcabene and derivatives for treating pancreatitis | |
CN111743869A (zh) | 一种匹伐他汀钙片剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: YAOSHI THERAPY COMPANY Free format text: FORMER OWNER: MICHIGAN LIFE THERAPEUTICS LLC Effective date: 20150127 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20150127 Address after: michigan Applicant after: Yao Shi treatment company Address before: Michigan Applicant before: Michigan Life Therapeutics, LLC |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1201452 Country of ref document: HK |
|
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20141105 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1201452 Country of ref document: HK |